Starling Oncology
STLN
117 hedge funds and large institutions have $137M invested in Starling Oncology in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 26 reducing their positions, and 18 closing their positions.
6,581% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $236K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
81% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 26
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
13% more capital invested
Capital invested by funds: $121M → $137M (+$16.1M)
8% more funds holding
Funds holding: 108 → 117 (+9)
2.04% more ownership
Funds ownership: 37.08% → 39.12% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
+$8.37M |
| 2 |
KWM
Kanen Wealth Management
Coconut Creek,
Florida
|
+$4.21M |
| 3 |
Jane Street
New York
|
+$2.52M |
| 4 |
BlackRock
New York
|
+$1.74M |
| 5 |
JP Morgan Chase
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.85M |
| 2 |
Millennium Management
New York
|
-$2.81M |
| 3 |
TAS
TIFF Advisory Services
Radnor,
Pennsylvania
|
-$2.45M |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$2.2M |
| 5 |
EFI
EHP Funds Inc
Toronto,
Canada
|
-$852K |
STLN Hedge Fund Activity: Q4 2025 in Review
117 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q4 2025, worth a combined $137M — up 13% from $121M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new STLN positions and 18 closed out — a net gain of 11 holders — while 47 added to existing stakes and 26 trimmed.
The largest buyer was Josh Arnold Investment Consultant, adding an estimated $8.37M. The largest seller was UBS Group, cutting an estimated $2.85M.
- 117 institutional investors held Starling Oncology (STLN) as of Q4 2025, up from 108 in Q3 2025.
- Funds reported $137M of Starling Oncology stock for Q4 2025, up 13% quarter-over-quarter.
- 29 funds opened new Starling Oncology positions in Q4 2025 and 18 closed out, a net change of +11 holders.
- The largest Starling Oncology buyer in Q4 2025 was Josh Arnold Investment Consultant, an estimated $8.37M added.
- The largest Starling Oncology seller in Q4 2025 was UBS Group, an estimated $2.85M sold.
Based on aggregated 13F filings for Q4 2025.